PTPA and hematologic disorder: SET (or I2PP2A) is a potent endogenous inhibitor of the tumor-suppressor PP2A (8) as PP2A acts as a negative regulator of several survival and proliferation pathways that are aberrantly activated in hematological malignancies (8).